S
exual dysfunction has been identified in up to 40% of women 1,2 with hypoactive sexual desire, representing at least a quarter of these women. [3] [4] [5] Acknowledging that there has been controversy regarding the definition and diagnosis of hypoactive sexual desire in women, hypoandrogenism [6] [7] [8] [9] has been identified as an etiology of hypoactive sexual desire, consistent with the obligatory role of testosterone to increase libido, frequency of and satisfaction with sexual activity, and orgasm in men. 10 Furthermore, testosterone has beneficial effects in women on arousal, pleasure, responsiveness, and satisfaction [6] [7] [8] [10] [11] [12] [13] [14] and has been shown to be effective as treatment for hypoactive sexual desire disorder in clinical trials of testosterone administration in women. Sexual dysfunction has been described to be prevalent in couples with infertility, possibly as a side effect of frustration regarding their inability to conceive. However, data on the association of underlying infertility diagnosis with sexual dysfunction are limited.
To elucidate sexual dysfunction in well-characterized couples with polycystic ovary syndrome (PCOS) and unexplained infertility (UI) and to assess correlations of sexual function and dysfunction in female partners of infertile couples, we undertook a secondary analysis of data from 2 studies of the Eunice Kennedy Shriver National Institutes of Child Health and Human Development Cooperative Reproductive Medicine Network (RMN). Additionally, we sought to test the hypothesis that circulating androgen, as assessed by free androgen index (FAI) in women, would be inversely related to the prevalence of sexual dysfunction.
Materials and Methods Patients
We performed a cross-sectional secondary data analysis of the RMN's Pregnancy in Polycystic Ovary Syndrome Study (PPCOS II) 11, 12 and Assessment of Multiple Intrauterine Gestations from Ovarian Stimulation (AMIGOS) 13, 14 clinical trials, which were conducted concurrently at multiple sites in the United States.
All PPCOS II women were seeking infertility care and were between the ages of 18 and 39 years; had oligoovulation, defined by the modified Rotterdam criteria for this disorder; and had exclusion of other disorders that could mimic the syndrome, such as congenital adrenal least 5 million motile sperm on semen analysis; and were also seeking infertility care. 15, 16 All couples from both concurrent clinical trials were asked to complete several psychosocial instruments at the time of screening. Each protocol was approved by the institutional review board at each study site; all participants gave written informed consent prior to initiating participation in the study. The study design and main outcomes for each protocol has been previously published. 12, 13, 17, 18 Briefly, the PPCOS II trial was designed to test whether letrozole was a superior treatment to clomiphene of ovulation induction and achievement of a live birth in women with PCOS. 11, 12 Seven hundred fifty female participants and their partners enrolled into the PPCOS II trial. Of these, 733 women (97.7%) completed the questionnaires.
The AMIGOS trial was designed to test whether letrozole was more effective at producing monofollicular development and therefore result in fewer multiple pregnancies than either clomiphene or gonadotropins while being similarly effective to these medications. The AMIGOS trial enrolled 900 women and their partners; 865 women (96.1%) completed the questionnaires.
Sexual function and quality-of-life assessments
Female sexual function was assessed in both protocols in an identical fashion as previously described. 17, 18 Briefly, female sexual function was assessed by the Female Sexual Function Inventory (FSFI) along with the Female Sexual Distress Scale (FSDS). 19 The FSFI is comprised of 6 domains (desire, arousal, lubrication, orgasm, satisfaction, and pain) with score ranges of 0 (or 1) to 5. The full score range is 2.0e36, with higher scores associated with better sexual function. The FSFI measure is considered the gold standard assessment of sexual function and has excellent psychometric properties. 19 The FSDS is a 13 item questionnaire that measures sexually related personal distress in women, with higher scores indicating greater personal distress.
Quality-of-life assessment was conducted in identical fashion in both protocols by the Medical Outcomes Survey 20 and Short-Form 36. 21 Quality of life relating to infertility was assessed using the FertiQoL survey.
22,23

Analytic measurements
At screening, the visits were standardized across all study sites, and each site used identical case report forms prepared by the RMN Data Coordination Center at Yale University. Forms and procedures for data collection were identical for both cohorts.
Body mass index (BMI) was calculated from height and weight measurements performed at the screening visit. Participants were weighed while dressed in light clothing, without shoes. Height was measured without shoes.
Couples were administered a basic demographic questionnaire that collected information about educational attainment in categories (high school education or less; college education or some college; graduate level education) and income (household income less than or greater than $50,000 per year). Hirsutism was assessed in all participants using the Ferriman-Gallwey hirsutism scoring scale. 24 Blood specimens for each subject were collected at one time prior to administration of any study medications. All hormone analyses from both protocols 
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A and B, Mean and SD of hormones between patients with polycystic ovarian syndrome and unexplained infertility. Asterisk indicates a value of P < .001.
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were measured by the University of Virginia Core Laboratory as previously described. 11, 12, 14 Briefly, subject serum samples were assayed in singlet with 5% run in duplicate (both randomly selected and for outliers).
Steroid assays
Total testosterone (TT), estradiol, progesterone, and 17-alpha hydroxyprogesterone caproate (17OHP-C) were measured using commercial radioimmunosorbent assays (Siemens, Los Angeles, CA). Dehydroepiandrosterone sulfate (DHEAS) was measured on the Siemens Immulite 2000 automated chemiluminescent immunoassay analyzer. The limit of quantitation (functional sensitivity) was defined as the lowest concentration that demonstrates accuracy within 20% of expected values and intraassay coefficient of variation (%CV) <20% and was determined by serial dilutions of a defined sample pool.
For TT, intraassay and interassay % CVs were 4.3% and 7.4%, respectively; functional sensitivity was 10 ng/dL. Estradiol and intraassay and interassay %CVs were 5.4% and 6.5%, respectively; functional sensitivity was 10 pg/mL. For progesterone, intraassay and interassay %CVs were 4.4% and 7.8%, respectively; functional sensitivity was 0.1 ng/mL. 17OHP-C was 4.9% (intraassay), 6.9% (interassay), and 0.15 ng/mL (functional sensitivity). For DHEAS, intraassay and interassay %CVs were 5.4% and 6.5%, respectively; functional sensitivity was 15 mg/dL.
Protein assays
Luteinizing hormone (LH), folliclestimulating hormone (FSH), thyrotropin (TSH), and sex hormoneebinding globulin (SHBG) were measured on the Siemens Immulite 2000. Intraassay and interassay coefficients of variation s and functional sensitivity for LH was 3.3%, 5.6%, and 0.1 mIU/mL, respectively; 3.2%, 4.9%, and 0.1 mIU/mL, respectively, for FSH; 3.6%, 4.7%, and 0.004 mIU/mL, respectively, for TSH; and 2.7%, 5.2%, and 2.0 nmol/L, respectively, for SHBG.
Quality controls (QCs)
Bio-Rad Laboratories (Hercules, CA) trilevel human serum QCs were included in all assays used for the present study. To identify the kit lot-to-lot shifts over the course of the study, all assays included a single lot of Bio-Rad Laboratories Tri-Level QCs (lot 270).
Free androgen index
The FAI was calculated as TT (in nanomoles per liter)/SHBG (in nanomoles per liter).
Statistical methods
Analysis was conducted using the combined patients (women only) from the PPCOS II trial (n ¼ 750) and AMIGOS trial (n ¼ 900). Of these 1650 women, 56 were excluded from analysis because of incomplete data. The combined population was divided into 2 groups: participants from the PPCOS II study (PCOS patients) and participants from the AMIGOS study (UI patients). Summary statistics are reported for demographic variables, hormonal parameters, physical and phenotypic characteristics, and sexual function measures in each of the 2 groups. Categorical data are reported as frequencies and percentages; differences in these measures between the 2 groups were assessed by means of a c 2 analysis, with a Fisher exact test used for expected frequencies of less than 5.
Continuous data are reported as n, number of participants, and mean (SD), with a Wilcoxon rank-sum test used for testing differences between the 2 groups. A linear multivariable model analysis was also performed to investigate the association between sexual function measures and patient groups; variables that showed significant differences (P < .05) between the 2 groups were included as covariates for the adjustments. ajog.org
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All statistical analyses were performed in SAS version 9.4 (SAS Institute, Cary, NC). Statistical significance was defined as a 2-sided value of P < .05.
Results
Comparing the PCOS and UI populations, many of the demographic characteristics of the female partner, including age, race, ethnicity, marital status, level of education, occupation, annual household income, and insurance type (Table 1) were statistically significantly different. Notably, the PCOS population had an increased prevalence of metabolic syndrome (34.2% vs 13.1% for women with UI, P < .001). PCOS women reported higher levels of current smoking (34.0% vs 22.1%, respectively) and a lower current alcohol use (71.3% vs 83.5%, respectively, P ¼ .001).
Women with PCOS had higher weight (P < .001) and BMI (P < .001) than the women with UI (Table 2) .
Clinical manifestations of androgen excess were also far more common in the women with PCOS, as noted for the Ferriman-Gallwey hirsutism score, (P < .001), sebum score (P < .001), and acne score (P < .001).
Comparing women with PCOS with women with UI, LH levels were higher (P < .001). Androgen levels were higher in women with PCOS as compared with women with UI, with levels being 2-fold higher for testosterone (P < .001), and nearly 4-fold higher for free testosterone (P <0.001) and DHEAS (P < .001). Consistent with these observation, SHBG levels were nearly double in the women with UI as compared with those with PCOS (P < .001). 17OHP-C levels were also considerably higher in women with PCOS (P < .001) ( Figure, A and B) .
The FSFI total scores (Table 3) in women with PCOS and UI were nearly identical (29.9 AE 4.6 vs 29.9 AE 4.9, respectively; P ¼ NS). Among the FSFI subscores, there were no differences in the physiologic arousal, subjective arousal, orgasm, or satisfaction subscores. The desire subscore was statistically higher in the women with PCOS (P ¼ .007), while the pain subscore was statistically higher in the with UI women (P ¼ .001), although these differences are not likely of clinically significance.
Consistent with these observations, there were no differences in the Fertility Quality of Life Questionnaire, with the exception of a statistical difference in the difficulty to express feelings, which was slightly lower in the PCOS group (P < .001). The FSDS total score was higher in women with PCOS than those with UI (P ¼ .004), with a small difference reported in being bothered by low sexual desire but no difference in satisfaction with their sex life.
After the adjustment in the multivariable analyses, none of the previously mentioned sexual function measures If the total study population (PCOS and UI) is divided into quintiles of FAI, the FSFI total score increases from the first quintile score of 29.1 AE 5.3 to a fifth quintile score of 30.5 AE 4.0 (P ¼ .010; Table 5 ). This change was most prominently driven by an increase in Mean ( Original Research GYNECOLOGY ajog.org the desire subscore (P < .001), with a very small but significant increase in the physiological arousal subscore (P ¼ .019) and the subjective arousal subscore (P ¼ .026).
Similar observations were observed when data were examined in tertiles as opposed to quintiles (data not shown). Additionally, a similar trend was observed when sexual function was assessed by quintiles of TT levels but reached significance only for the desire subscore (P <0.001; data not shown).
When the relationship between the FSFI score and FAI is examined by diagnosis (PCOS vs UI), the women with PCOS had relatively high FAI values; for example, the lowest FAI quintile include FAI levels up to 3.24. Interestingly, a trend for increasing FSFI score with increasing FAI levels was observed, although this did not reach statistical significance (data not shown). Among women with UI, the highest quintile had FAI values >2.53%.
In this population, FSFI levels were significantly related to FAI quintile (P ¼ .001) with significant differences in the desire subscore (P ¼ .005), physiological arousal subscore (P ¼ .005), and subjective arousal subscore (P ¼ .002) ( Table 6 ). There were no significant differences in the FSFI orgasm, pain, or satisfaction subscores in relation to the FAI quintile. Similarly, there were no significant differences in the FSDS total score or dissatisfaction with sex life subscore, except bothered by low desire subscores (P ¼ .004) based on the FAI quintile.
The relationship between sexual function measures and female BMI and race and ethnicity was investigated. As shown in Table 7 , patients with a higher BMI had a significantly higher FSFI total and subscores (except the satisfaction score). Hispanic or Latino women had a significantly higher FSFI total and subscores (P < .001) and lower FSDS scores (P < .001), indicating a higher quality of life (Table 8) .
Comment
Sexual dysfunction has been associated with low circulating androgen levels both during natural menopause and in relation to surgically induced menopause. [25] [26] [27] [28] [29] Furthermore, improvements in several components of sexual dysfunction are observed with testosterone administration. 4, 6, 25, [29] [30] [31] [32] Limited data addressing the relationship of circulating androgens with sexuality in premenopausal women are available. Thus, we sought to assess sexual function in 2 wellcharacterized populations of women with infertility with markedly different ovulatory and circulating androgen phenotypes.
As expected, and by definition, the PCOS women exhibited greater clinical androgen manifestations, as evidenced by increased hirsutism, sebum, and acne. Consistent with this clinical phenotype, the women with PCOS had elevated levels of testosterone (both total and free) and DHEAS, with lower SHBG levels. Although many demographic characteristics differed between the groups with statistical significance, these differences likely did not have a substantial impact on sexual function and dysfunction with the exception of the difference in weight and BMI in the women with PCOS compared with UI.
Women with PCOS were more bothered by their weight and were slightly more bothered by lower sex desire than those with UI. Nonetheless, women with higher BMI showed significantly higher FSFI total and subscores (except for the satisfaction subscore).
Interestingly, the androgenic phenotypic and hormonal profile in the women with PCOS was not associated with a difference in the FSFI scores as compared with women with UI who were less androgenic. Some contradictions were observed in the women with PCOS including a higher Original Research GYNECOLOGY ajog.org sexual desire subscore on the FSFI but being more bothered by low sexual desire on the FSDS and being bothered by less sexual desire on the Patient Health questionnaire.
A possible interpretation is that the women with PCOS had greater sexual desire but were not satisfied with that level of sexual desire. However, although all differences in scores were statistically significant, the absolute differences in each of the scores was small (0.1 increment in each score of total scores of 6, 4, and 3, respectively), with multivariate analysis indicating no significant differences. ajog.org
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Overall, our observations are not consistent with studies demonstrating marked effects of testosterone to increase libido in female animals. This may represent a tamping effect of perceived psychosocial normal human behavior. Alternatively, it may represent a saturation of testosterone's effect on libido in women with high androgen levels as observed in the PPCOS II study because an increase in sexual desire with rising testosterone levels was more pronounced in the women in the AMIGOS study, in whom there was a greater range in the testosterone levels.
We found that the increasing FAI was associated with a small but significant increase in FSF scores. Interestingly, the strongest FSFI subscore component correlating with the FAI was for the desire subscore, generally the prominent feature of hypoactive sexual desire disorder and found by others to have a positive impact by exogenous testosterone treatment, [30] [31] [32] which would increase serum androgens.
Significant differences in the physiological arousal and subjective arousal subscore were also identified. Nevertheless, the FSDS scores were consistent across the FAI quintiles, clearly demonstrating that this large population of infertile women did not consider themselves to be dissatisfied with their sex life.
Of note, the prevalence of women with FSDS scores !15 was 14.7% in the infertile women in the RMN studies, which is less than the rate of 22.8% of 31,581 women over the age of 18 years from a national research panel considered to be representative of US women. 2 There are many strengths of this secondary analysis. These include the large sample size, the use of validated questionnaires, the measurement of androgens in a single reference laboratory, and the well-characterized population of reproductive age (not menopausal) women. Additionally, the FSFI and FSDS questionnaires were obtained at a single time point in each study prior to the initiation of treatment, which may be considered a limitation of this analysis. Another limitation of the study is the absence of a fertile control group with which to compare these findings in infertile women.
In summary, we have characterized sexual function in 2 large distinct reproductive-age groups of infertile women with the polycystic ovarian syndrome and unexplained infertility. Despite statistically different demographics and greater phenotypical and hormonal androgenicity in the women with PCOS, the FSFI total scores were nearly identical. n
